Markets:

Overview

News

Currencies

International

Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

0.9490 +0.0491 (+5.46%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revelation Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

January 14, 2026

Via ACCESS Newswire

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2026

Via ACCESS Newswire

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

January 07, 2026

Via ACCESS Newswire

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

December 01, 2025

Via ACCESS Newswire

Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug ↗

September 09, 2025

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 20, 2025

Via Benzinga

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

November 20, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

REVELATION BIOSCIENCES INC (NASDAQ:REVB) Reports Q3 2025 Loss, Announces Groundbreaking Clinical Data and Improved Cash Runway ↗

November 06, 2025

Revelation Biosciences posts wider Q3 loss but secures funding, extends cash runway into 2026 following positive Gemini study data.

Via Chartmill

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

November 06, 2025

Via ACCESS Newswire

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

October 29, 2025

Via ACCESS Newswire

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

October 15, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 11, 2025

Via Benzinga

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

September 11, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 10, 2025

Via Benzinga

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

September 10, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 09, 2025

Via Benzinga

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

September 09, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 09, 2025

Via Benzinga

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

September 09, 2025

Via ACCESS Newswire

Revelation Biosciences Inc (NASDAQ:REVB) Reports Wider-Than-Expected Q2 2025 Loss, Extends Cash Runway to Year-End ↗

August 08, 2025

Revelation Biosciences (REVB) reports Q2 2025 earnings with a wider-than-expected loss of $(7.01) per share. Cash runway extends to December 2025, while Phase 1b Gemini trial data for CKD is expected...

Via Chartmill

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

August 08, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

July 24, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

July 16, 2025

From Revelation Biosciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 02, 2025

Via Benzinga

US Stocks Likely To Open Higher: S&P 500 Sees 'Average Gain Of 6.1%' In 2nd Half, Expert Says ↗

July 02, 2025

U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.

Via Benzinga

Topics Stocks

Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’ ↗

July 01, 2025

The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly.

Via Stocktwits

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

July 01, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Which stocks have an unusual volume on Wednesday? ↗

June 04, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.

Via Chartmill

Wondering what's happening in today's after-hours session? ↗

June 03, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.